Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib and PegIFN-alpha2b in CML Patients with Suboptimal Response to Imatinib
NCT01866553Phase 2Terminated
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2013
- Primary completion
- Apr 2016
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons, Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of nilotinib and peginterferon alfa-2b in chronic myeloid leukemia (CML), sponsored by Amsterdam University Medical Center. Primary endpoint: Proportion of patients achieving confirmed MR4.0 at 12 months. Started Apr 2013; status: terminated.
02
Drugs
nilotinibpeginterferon alfa-2b
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01866553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01866553.